US-based Zeda Holdings, which uses 3D printing to manufacture orthopaedic implants, is planning to raise up to $200 million in capital for its India foray, its chief executive officer, Shri Shetty, told ET.#Elections with ETLok Sabha Exit Poll Results 2024: Track all updates hereThe company is exploring options in India, including tie-ups with pan-India distributors, joint ventures in which the partner will co-invest, and acquisition of local medical technology companies, according to Shetty.A significant part of the proposed fund raise will be used for setting up multiple small (10,000-20,000 sq ft) yet fully automated facilities in India to do metal 3D printing using advanced semiconductor device fabrication process to manufacture orthopaedic implants targeting trauma and spine surgeries.On its India entry strategy, Zeda is being advised by Wodehouse Capital Advisors.'We're looking for partners and local capital,' Shetty said.

总部位于美国的泽达控股公司（Zeda Holdings）使用3D打印技术制造整形外科植入物，其首席执行官谢蒂（Shri Shetty）告诉ET.#选举与埃特洛克·萨巴（ETLok Sabha）2024年退出投票结果：跟踪所有更新据谢蒂（Shetty）称，该公司正在印度探索各种选择，包括与泛印度分销商合作，合作伙伴将共同投资的合资企业以及收购当地医疗技术公司。拟议资金筹集的很大一部分将用于在印度建立多个小型（10000-20000平方英尺）但全自动化的设施，使用先进的半导体器件制造工艺进行金属3D打印，以制造针对创伤和脊柱手术的骨科植入物。关于Zeda的印度进入战略，Wodehouse Capital Advisors为其提供咨询谢蒂说，我们正在寻找合作伙伴和当地资本。

'We will use part of the capital for buying some local entities, part of it (will be) used for creating a local team, and the remaining half capital is used for building a factory, doing a joint venture.'Zeda has 52 USFDA-approved products implanted in more than 32,000 patients. The company offers more than 30 trauma devices and instruments.

“我们将用一部分资金购买一些当地实体，一部分资金用于组建当地团队，剩下的一半资金用于建造工厂和合资企业。”Zeda在32000多名患者中植入了52种美国食品和药物管理局批准的产品。该公司提供30多种创伤器械。

It has over 150,000 sq ft of manufacturing footprint across the US.Shetty said Zeda's focus in India will be on trauma implants, which account for about $3 billion of India's $8-billion orthopaedic implants market.'The USFDA-approved implants are expensive. The locally used ones, which were relatively cheaper, are imported from China, Czech Republic, Pakistan and other countries,' Shetty said.

它在美国拥有超过15万平方英尺的制造足迹。Shetty说，Zeda在印度的重点将是创伤植入物，在印度80亿美元的骨科植入物市场中，创伤植入物约占30亿美元USFDA批准的植入物价格昂贵。谢蒂说，当地使用的相对便宜，是从中国、捷克共和国、巴基斯坦和其他国家进口的。

'We can bring the cost down due to local factories, which means that we can sell USFDA implants at very comparable p.

“由于当地工厂的存在，我们可以降低成本，这意味着我们可以以非常可比的价格销售USFDA植入物。